
Anupam Rasayan Analyst Review 2027: EBITDA Up 41% as Fluorine Mix Lifts Margins
Updated: 19 Nov 2026 • 4:10 pm
Posted by:

Anupam Rasayan India Stock Snapshot (19 Nov 2026)
- Current Market Price (CMP): ₹1,328.00
- 52-Week High / Low: ₹1,415.00 / ₹1,067.80
- Market Capitalisation: ₹15,118 crore
- P/E Ratio vs Industry P/E: 64.9 vs 33.3
- Latest Quarter (Q2 FY27) Revenue: ₹821.18 crore
- Latest Quarter (Q2 FY27) Net Profit: ₹64.97 crore
Quick Answer: The Anupam Rasayan analyst review 2027 finds one recent named brokerage view: Deven Choksey Research has an Accumulate rating with a ₹1,374 target from August 2026, about 3.5% above the ₹1,328 price on 19 November 2026. Q2 FY27 revenue rose 11.1% to ₹821.18 crore, EBITDA rose 41% to ₹202.47 crore and net profit rose 13.7% to ₹64.97 crore. The stock trades at about 65 times trailing earnings, so the Anupam Rasayan share price target 2027 debate rests on whether earnings growth catches up with the margin gains.
The Anupam Rasayan analyst review 2027 looks at a Surat-based custom synthesis and speciality chemicals maker that has moved heavily into fluorination chemistry over the past three years. Readers searching for an Anupam Rasayan share price target 2027 will find limited, mixed coverage, so this review leans on the September quarter numbers, the order book and valuation.
Anupam Rasayan traded at ₹1,328 on 19 November 2026, about 6% below its 52-week high of ₹1,415 and about 24% above its low of ₹1,067.80. This Anupam Rasayan analyst review 2027 explains what drove the quarter and what shapes the Anupam Rasayan stock outlook 2027.
Click Here – Get Free Investment Predictions
What Analysts Say in the Anupam Rasayan Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| Deven Choksey Research | Accumulate | ₹1,374 | August 2026 |
| Emkay Global | Add | ₹1,050 | December 2025 (older view) |
Deven Choksey Research raised its target price to ₹1,374 after the June quarter, valuing the stock at about 38 times its FY28 earnings estimate. That target sits only about 3.5% above the current price, so the stock has already moved close to the most recent named view. The Emkay figure is from December 2025, before the FY26 results, and is shown only as an older reference point in this Anupam Rasayan analyst review 2027.
No fresh named brokerage note after the September quarter could be verified as of 19 November 2026. Readers should treat the table as a guide to how analysts value the stock rather than a live consensus.
Q2 FY27 Results in the Anupam Rasayan Analyst Review 2027
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue | ₹821.18 crore | ₹739.19 crore | Up 11.1% |
| EBITDA | ₹202.47 crore | ₹143.58 crore | Up 41.0% |
| EBITDA margin | About 24.7% | About 19.4% | Up about 530 bps |
| Net profit | ₹64.97 crore | ₹57.15 crore | Up 13.7% |
| H1 FY27 net profit | ₹116.19 crore | About ₹106 crore | Up about 10% |
Revenue grew at a low double-digit pace, but EBITDA margin widened by about 530 basis points as higher-value fluorinated products made up a bigger share of sales. The September quarter was also the strongest of the last five quarters on revenue, EBITDA and profit.
Net profit grew far slower than EBITDA because interest and depreciation have risen after recent acquisitions and capacity additions. That gap is the main reason the Anupam Rasayan analyst review 2027 sees earnings, rather than margins, as the number to watch next.
Operating cash flow was about ₹328 crore in the first half, a sharp improvement on the weak cash generation of FY25. Better cash conversion matters because the company has spent heavily on plants and deals.
How Anupam Rasayan Makes Money
Anupam makes complex intermediates under long-term contracts for global agrochemical, pharmaceutical and performance-material customers.
- Life science chemicals: about 42% of Q2 revenue, mainly agrochemical and pharma intermediates.
- Performance materials: about 28% of revenue, used in polymers, electronics and personal care.
- Other fluorinated products: about 29% of revenue, a segment that has grown after the Tanfac acquisition.
- Pharma push: the Bliss GBS Pharma acquisition adds a route into pharmaceutical manufacturing.
FY26 revenue rose to ₹2,383.6 crore from ₹1,448.5 crore in FY25, while net profit rose to ₹222.2 crore from ₹160 crore. Those numbers frame the Anupam Rasayan analyst review 2027, because the revenue base has grown far faster than profit.
Custom synthesis work runs on multi-year letters of intent, which give visibility but also concentrate revenue in a small number of large global clients. The company reports an order book of about ₹17,500 crore and has guided for more than 30% revenue growth in FY27, which would need a much stronger second half than the first.
The September quarter already shows part of that pickup. Revenue rose about 23% from the June quarter, from ₹667.55 crore to ₹821.18 crore, and EBITDA rose about 16% over the same period. If the company holds the second-quarter run rate and adds new molecules on schedule, full-year growth could move closer to guidance, though it would still need the December and March quarters to be larger still. Investors comparing the stock with the large companies in the Nifty 50 should note that Anupam's earnings swing more from quarter to quarter because a few big contracts drive its revenue.
Growth Triggers in the Anupam Rasayan Analyst Review 2027
- Margin expansion: EBITDA margin near 25% from about 19% a year ago.
- Order book: about ₹17,500 crore of contracted work across customers.
- Fluorination capacity: a growing share of higher-value products.
- Cash flow: about ₹328 crore of operating cash in H1 FY27.
- Guidance: more than 30% revenue growth in FY27, central to any Anupam Rasayan share price target 2027.
Key Risks in the Anupam Rasayan Analyst Review 2027
- High valuation: about 65 times trailing earnings against an industry level near 33.
- Profit lag: profit rose only 13.7% while EBITDA rose 41%.
- Client concentration: a few global customers drive most revenue.
- Agrochemical cycle: global destocking can delay orders.
- Execution: new plants and acquisitions must deliver, a core point in the Anupam Rasayan analyst review 2027.
Compare Anupam Rasayan With Other Speciality Chemical Stocks on the Univest Screener
Anupam Rasayan Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (19 Nov 2026) | ₹1,328.00 |
| 52-Week High / Low | ₹1,415.00 / ₹1,067.80 |
| Market Capitalisation | About ₹15,118 crore |
| P/E (TTM) | About 64.9 |
| Industry P/E | About 33.3 |
| Price to Book | About 3.0 |
| Return on Equity | About 4.6% |
| Debt to Equity | 0.50 |
| FY26 Revenue / Net Profit | ₹2,383.6 crore / ₹222.2 crore |
The P/E of about 65 is nearly double the industry level, while return on equity is in single digits. In this Anupam Rasayan analyst review 2027, the premium reflects the order book and margin gains, but it leaves little room for a weak quarter.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 59.07% | 59.07% | No change |
| Foreign Investors (FII) | 7.63% | 8.66% | Up 1.03 points |
| Domestic Institutions (DII) | 1.37% | 0.44% | Down 0.93 points |
| Public | 31.92% | 31.83% | Down 0.09 points |
The promoter group, led by Kiran Pallavi Investments with 31.8% and Anand Desai with 9.73%, held its stake steady. Foreign investors added about one percentage point while domestic institutions cut back, a mixed signal in the Anupam Rasayan analyst review 2027.
What to Watch After the Anupam Rasayan Analyst Review 2027
- Second-half revenue: whether growth reaches the 30% plus guidance.
- Margins: EBITDA margin holding near 25%.
- Profit conversion: interest and depreciation against EBITDA growth.
- New contracts: fresh letters of intent from global clients.
- Coverage: post-Q2 notes that update the Anupam Rasayan share price target 2027.
Final Word on the Anupam Rasayan Analyst Review 2027
The Anupam Rasayan analyst review 2027 shows a company with a much stronger margin profile, better cash flow and a large order book, held back by slower profit growth and a rich valuation. The latest named target is close to the current price.
The Anupam Rasayan stock outlook 2027 depends on second-half delivery and profit conversion. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Anupam Rasayan analyst review 2027 show?
It shows strong margin improvement with slower profit growth. Q2 FY27 EBITDA rose 41% to ₹202.47 crore and margin widened to about 24.7%. Net profit rose 13.7% to ₹64.97 crore on revenue of ₹821.18 crore, up 11.1%.
What is the Anupam Rasayan share price target 2027 from brokerages?
Deven Choksey Research has an Accumulate rating with a ₹1,374 target from August 2026. That is about 3.5% above the ₹1,328 price on 19 November 2026. An older Emkay Global target of ₹1,050 dates from December 2025.
Why did Anupam Rasayan's profit grow slower than EBITDA?
Interest and depreciation have risen after acquisitions and new capacity. EBITDA rose about ₹59 crore year on year, but net profit rose only about ₹8 crore. Better profit conversion is the key test for the coming quarters.
What is Anupam Rasayan's revenue mix?
Life science chemicals made up about 42% of Q2 FY27 revenue. Performance materials contributed about 28% and other fluorinated products about 29%. The company is also adding pharma manufacturing through the Bliss GBS Pharma acquisition.
Is Anupam Rasayan stock expensive based on the Anupam Rasayan analyst review 2027?
The stock trades at about 65 times trailing earnings, nearly double the industry level of about 33. Price to book is about 3.0, while return on equity is about 4.6%. The premium assumes strong earnings growth from the order book.
What risks does the Anupam Rasayan analyst review 2027 highlight?
The main risks are the high valuation, slow profit growth and dependence on a few global customers. Agrochemical destocking can delay orders. Debt to equity of 0.50 also adds interest costs.
What should investors track after the Anupam Rasayan analyst review 2027?
Track whether second-half revenue supports the 30% plus growth guidance for FY27. Watch EBITDA margin around 25% and how much of it reaches net profit. New contracts against the ₹17,500 crore order book also matter.
Recent Articles

Unicommerce eSolutions Share Price Target 2027: What Earnings Say About Rs 99.8 and Rs 119
19 November 2026

Tera Software Share Price Target 2027: Rs 372 Base, Rs 446 Bull and the Risks to Watch
19 November 2026

Techno Electric and Engineering Company Share Price Target 2027: 20.1% Upside to Rs 1,123
19 November 2026

Seshaasai Technologies Share Price Target 2027: Can It Reach Rs 443? Base Case at Rs 367
19 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Unicommerce eSolutions Share Price Target 2027: What Earnings Say About Rs 99.8 and Rs 119
Tera Software Share Price Target 2027: Rs 372 Base, Rs 446 Bull and the Risks to Watch
Techno Electric and Engineering Company Share Price Target 2027: 20.1% Upside to Rs 1,123
Seshaasai Technologies Share Price Target 2027: Can It Reach Rs 443? Base Case at Rs 367
Silver Touch Technologies Share Price Target 2027: 20.1% Upside to Rs 151, Bull Case Rs 180

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





